Komori
Precision System Science (7707) · FactRestated

Change of Audit Firm for Quarterly Reviews

First written in FY2018-Q1. 10 of 16 entries say "Restated". Latest entry: FY2025.

16entries
9years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2019-Q3 – FY2020RestatedFY2021-Q2 – FY2023-Q22017: 12018: 120182019: 220192020: 320202021: 220212022: 320222023: 120232024: 120242025: 22025
Same theme, other companies
Change in Independent AuditorA theme 778 companies write about · 1 as a headwind · 37 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 200 companies compared. The sentences above are computed from all 200.Comparing 200 of the theme's 778 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2025RestatedAnnual report

    「Fiscal year 40 (1 July 2024 to 30 June 2025): ＨＬＢ Ｍｅｉｓｅｉ有限責任監査法人.」

    The change decided in the previous fiscal year from OAG監査法人 to HLB Meisei有限責任監査法人 has continued as the statutory audit for the current fiscal year under the Companies Act.
  2. FY2025-H1AchievedAnnual report

    「Pursuant to Article 193-2, Paragraph 1 of the Financial Instruments and Exchange Act, the Company has undergone an interim review by HLB Meisei有限責任監査法人 of its interim consolidated financial statements for the interim consolidated accounting period (1 July 2024 to 31 December 2024).」

    The change decided in FY2024 from OAG監査法人 to HLB Meisei有限責任監査法人 was implemented through the interim review for the current interim consolidated accounting period.
  3. FY2024AdvancedAnnual report

    「Fiscal year 39 (1 July 2023 to 30 June 2024): ＯＡＧ監査法人; fiscal year 40 (1 July 2024 to 30 June 2025): ＨＬＢ Ｍｅｉｓｅｉ有限責任監査法人.」

    At the annual general meeting of shareholders held on 27 September 2024, the change from OAG監査法人 to HLB Meisei有限責任監査法人 was approved, formalizing the audit firm for the following fiscal year.
  4. FY2023-Q2RestatedAnnual report

    「Pursuant to Article 193-2, Paragraph 1 of the Financial Instruments and Exchange Act, the Company has undergone a quarterly review by ＯＡＧ監査法人 of its quarterly consolidated financial statements for the second-quarter consolidated accounting period (1 October 2022 to 31 December 2022) and the second-quarter consolidated cumulative period (1 July 2022 to 31 December 2022).」

    The quarterly review by OAG監査法人 continued to be conducted.
  5. FY2023-Q1RestatedAnnual report

    「Pursuant to Article 193-2, Paragraph 1 of the Financial Instruments and Exchange Act, the Company has undergone a quarterly review by ＯＡＧ監査法人 of its quarterly consolidated financial statements for the first-quarter consolidated accounting period (1 July 2022 to 30 September 2022) and the first-quarter consolidated cumulative period (1 July 2022 to 30 September 2022).」

    The quarterly review by OAG監査法人 has continued to be conducted.
  6. FY2022-Q3RestatedAnnual report

    「Pursuant to Article 193-2, Paragraph 1 of the Financial Instruments and Exchange Act, the Company has undergone a quarterly review by ＯＡＧ監査法人 of its quarterly consolidated financial statements for the third-quarter consolidated accounting period (1 January 2022 to 31 March 2022) and the third-quarter consolidated cumulative period (1 July 2021 to 31 March 2022).」

    The quarterly review by OAG監査法人 has continued to be conducted.
  7. FY2022-Q2RestatedAnnual report

    「Pursuant to Article 193-2, Paragraph 1 of the Financial Instruments and Exchange Act, the Company has undergone a quarterly review by ＯＡＧ監査法人 of its quarterly consolidated financial statements for the second-quarter consolidated accounting period (1 October 2021 to 31 December 2021) and the second-quarter consolidated cumulative period (1 July 2021 to 31 December 2021).」

    The quarterly review by OAG監査法人 continued to be conducted.
  8. FY2022-Q1RestatedAnnual report

    「Pursuant to Article 193-2, Paragraph 1 of the Financial Instruments and Exchange Act, the Company has undergone a quarterly review by ＯＡＧ監査法人 of its quarterly consolidated financial statements for the first-quarter consolidated accounting period (1 July 2021 to 30 September 2021) and the first-quarter consolidated cumulative period (1 July 2021 to 30 September 2021).」

    The quarterly review by OAG監査法人 continued to be conducted.
  9. FY2021-Q2RestatedAnnual report

    「Pursuant to Article 193-2, Paragraph 1 of the Financial Instruments and Exchange Act, the Company has undergone a quarterly review by ＯＡＧ監査法人 of its quarterly consolidated financial statements for the second-quarter consolidated accounting period (1 October 2020 to 31 December 2020) and the second-quarter consolidated cumulative period (1 July 2020 to 31 December 2020).」

    The quarterly review by OAG監査法人 has continued to be conducted.
  10. FY2021-Q1AchievedAnnual report

    「Pursuant to Article 193-2, Paragraph 1 of the Financial Instruments and Exchange Act, the Company has undergone a quarterly review by ＯＡＧ監査法人 of its quarterly consolidated financial statements for the first-quarter consolidated accounting period (1 July 2020 to 30 September 2020) and the first-quarter consolidated cumulative period (1 July 2020 to 30 September 2020). The Company's audit firm has changed as follows: fiscal year 35: 仰星監査法人; the first-quarter consolidated accounting period and first-quarter consolidated cumulative period of fiscal year 36: ＯＡＧ監査法人.」

    The change decided in the previous fiscal year from 仰星監査法人 to OAG監査法人 began to be implemented through the first-quarter review of fiscal year 36.
  11. FY2020Decision to change the audit firmAnnual report

    「Fiscal year 35 (1 July 2019 to 30 June 2020): 仰星監査法人; fiscal year 36 (1 July 2020 to 30 June 2021): ＯＡＧ監査法人.」

    At the annual general meeting of shareholders held on 29 September 2020, the change from 仰星監査法人 to OAG監査法人 was approved. 仰星監査法人 had proposed not renewing the audit agreement after considering the accounting and audit systems, among other factors.
  12. FY2020-Q3RestatedAnnual report

    「Pursuant to Article 193-2, Paragraph 1 of the Financial Instruments and Exchange Act, the Company has undergone a quarterly review by 仰星監査法人 of its quarterly consolidated financial statements for the third-quarter consolidated accounting period (1 January 2020 to 31 March 2020) and the third-quarter consolidated cumulative period (1 July 2019 to 31 March 2020).」

    The quarterly review by 仰星監査法人 has continued to be conducted.
  13. FY2019RestatedAnnual report

    「Name of audit firm: Gyosei Audit Corporation」

    The statutory audit by 仰星監査法人 has continued.
  14. FY2019-Q3RestatedAnnual report

    「Pursuant to Article 193-2, Paragraph 1 of the Financial Instruments and Exchange Act, the Company has undergone a quarterly review by 仰星監査法人 of its quarterly consolidated financial statements for the third-quarter consolidated accounting period (1 January 2019 to 31 March 2019) and the third-quarter consolidated cumulative period (1 July 2018 to 31 March 2019).」

    The quarterly review by 仰星監査法人 has continued to be conducted.
  15. FY2018AchievedAnnual report

    「Previous fiscal year and previous fiscal year under the Companies Act: 新日本有限責任監査法人 (currently EY新日本有限責任監査法人); current fiscal year and current fiscal year under the Companies Act: 仰星監査法人.」

    The change in audit firm disclosed at the quarterly stage extended to the full-year audit, and 仰星監査法人 became the accounting auditor for the current fiscal year and the current fiscal year under the Companies Act.
  16. FY2018-Q1First statedAnnual report

    「The Company's audit firm has changed as follows: Fiscal year 32: 新日本有限責任監査法人; the first quarter accounting period and first-quarter cumulative period of fiscal year 33: 仰星監査法人.」

    The audit firm changed from 新日本有限責任監査法人 to 仰星監査法人 from the first quarter of fiscal year 33.
Moved together

"Coexistence of the OEM Business and In-House Sales" moved the same way as this thread, in the same document, in 3 of its 16 moves.

333222★123456
  1. ★This thread
  2. 1Coexistence of the OEM Business and In-House Sales3×
  3. 2Expansion into Clinical Diagnostics Using the Fully Automated geneLEAD Genetic Diagnostic Instrument3×
  4. 3Expansion of production capacity for reagents and consumables using funds from the capital increase3×
  5. 4Fundamental Business Structure Reform and Earnings Improvement Measures2×
  6. 5Foreign exchange fluctuation risk arising from the scale of overseas sales2×
  7. 6Reducing selling, general and administrative expenses2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Precision System Science yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Change of Audit Firm for Quarterly Reviews | Precision System Science Co.,Ltd. (7707) | Komori